ArcticZymes Technologies reports strong Q2 biomanufacturing growth

ArcticZymes Technologies reported Q2 revenues of NOK 28.9 million, up 5% year-over-year, with biomanufacturing sales surging 52% to NOK 18.1 million. The successful launch of GMP-grade M-SAN HQ became the top-selling product. EBITDA increased 50% to NOK 3.9 million.

Molecular Tools declined 42% but secured NOK 16 million in new orders.